Melanomas arising in the uveal tract of the eye are a rare form of the disease with a biology
and clinical phenotype distinct from their more common cutaneous counterparts. Treatment …

Abstract Treatment of primary intraocular uveal melanoma has developed considerably, its
driver genes are largely unraveled, and the ways to assess its risk for metastases are very …

PURPOSE Metastatic uveal melanoma has poor overall survival (OS) and no approved
systemic therapy options. Studies of single-agent immunotherapy regimens have shown …

PURPOSE This study aimed to assess the efficacy of the combination of nivolumab (nivo)
plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) …

PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS ASCO convened an Expert Panel and conducted a systematic …

PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS American Society of Clinical Oncology convened an Expert Panel …

Uveal melanoma is an aggressive malignancy that originates from melanocytes in the eye.
Even if the primary tumor has been successfully treated with radiation or surgery, up to half …

The mitogen-activated protein kinase (MAPK) pathway plays a vital role in cellular
processes such as gene expression, cell proliferation, cell survival, and apoptosis. Also …

Background Despite the completion of numerous phase II studies, a standard of care
treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine …

Activating mutations in GNAQ/GNA11, encoding Gαq G proteins, are initiating oncogenic
events in uveal melanoma (UM). However, there are no effective therapies for UM. Using an …